BioEclipse Therapeutics™, a private clinical-stage biopharmaceutical company developing first-in-class, curative immuno-oncology therapeutics, announced today that its CEO and founder Pamela Contag, Ph.D., and CFO Ben Carter will participate in the Sachs 20th Annual Biotech in Europe Forum, taking place September 21–24, 2020 via a virtual platform.
|
MOUNTAIN VIEW, Calif., Sept. 18, 2020 /PRNewswire/ -- BioEclipse Therapeutics™, a private clinical-stage biopharmaceutical company developing first-in-class, curative immuno-oncology therapeutics, announced today that its CEO and founder Pamela Contag, Ph.D., and CFO Ben Carter will participate in the Sachs 20th Annual Biotech in Europe Forum, taking place September 21–24, 2020 via a virtual platform. Dr. Contag will host virtual one-on-one meetings with investors and potential partners to discuss BioEclipse's business strategy and highlight recent corporate achievements, as well as anticipated milestones in its clinical program for CRX100, BioEclipse's lead investigative candidate. Institutional investors are invited to request meeting times. To schedule a one-on-one meeting, please contact Dr. Contag or Mr. Carter at BioEclipse Therapeutics. CRX100 is an intravenously delivered cancer therapy designed to target and destroy multiple cancer types and to prevent disease recurrence. It only targets tumor cells, leaving healthy tissue untouched, but it has the ability to reach tumors throughout the body. This means CRX100 holds promise for metastatic disease treatment with limited toxicity. BioEclipse plans to initiate a Phase 1 clinical trial in therapy-refractory solid tumors before year end. About BioEclipse Therapeutics™ Contacts:
SOURCE BioEclipse Therapeutics |
View original content:
